Creating new treatments for antibiotic-resistant bacteria
Development of Therapeutic Products for Antibiotic Resistant Bacteria
['FUNDING_OTHER'] · MICROBIOTIX, INC · NIH-11140253
This study is working on creating new treatments to help fight infections caused by tough bacteria that don't respond to regular antibiotics, so patients can have better options for getting better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MICROBIOTIX, INC (nih funded) |
| Locations | 1 site (WORCESTER, UNITED STATES) |
| Trial ID | NIH-11140253 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new therapeutic products to combat antibiotic-resistant bacteria, particularly those that pose a threat to public health. The approach includes optimizing lead compounds, selecting the best candidates for further development, and conducting preclinical studies to ensure safety and efficacy. Patients may benefit from innovative treatments that could effectively target infections caused by resistant strains of bacteria, such as Pseudomonas aeruginosa. The research aims to advance these products through rigorous testing and regulatory processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
Not a fit: Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for infections caused by antibiotic-resistant bacteria, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in developing therapies for antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
WORCESTER, UNITED STATES
- MICROBIOTIX, INC — WORCESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOWLIN, TERRY — MICROBIOTIX, INC
- Study coordinator: BOWLIN, TERRY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Emerging Communicable Diseases, Emerging Infectious Diseases